DK1004582T3 - Pyradazinoquinolinforbindelser - Google Patents

Pyradazinoquinolinforbindelser

Info

Publication number
DK1004582T3
DK1004582T3 DK00101917T DK00101917T DK1004582T3 DK 1004582 T3 DK1004582 T3 DK 1004582T3 DK 00101917 T DK00101917 T DK 00101917T DK 00101917 T DK00101917 T DK 00101917T DK 1004582 T3 DK1004582 T3 DK 1004582T3
Authority
DK
Denmark
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
DK00101917T
Other languages
English (en)
Inventor
Thomas Michael Bare
Timothy Wayne Davenport
James Roy Empfield
Richard Bruce Sparks
Kinney Jeffrey Alan Mc
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1004582T3 publication Critical patent/DK1004582T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK00101917T 1993-10-22 1994-10-20 Pyradazinoquinolinforbindelser DK1004582T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
DK1004582T3 true DK1004582T3 (da) 2005-08-15

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00101917T DK1004582T3 (da) 1993-10-22 1994-10-20 Pyradazinoquinolinforbindelser
DK94930275T DK0724583T3 (da) 1993-10-22 1994-10-20 Pyridazino-quinolin-forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94930275T DK0724583T3 (da) 1993-10-22 1994-10-20 Pyridazino-quinolin-forbindelser

Country Status (29)

Country Link
US (3) US5744471A (da)
EP (2) EP0724583B1 (da)
JP (1) JP3583132B2 (da)
KR (1) KR100261209B1 (da)
CN (1) CN1053189C (da)
AT (2) ATE198072T1 (da)
AU (2) AU688393B2 (da)
CA (1) CA2171332A1 (da)
CZ (1) CZ292311B6 (da)
DE (2) DE69426422T2 (da)
DK (2) DK1004582T3 (da)
ES (2) ES2154686T3 (da)
FI (2) FI113865B (da)
GB (1) GB9420590D0 (da)
GR (1) GR3035080T3 (da)
HU (1) HUT74161A (da)
IL (1) IL111266A (da)
MY (2) MY124316A (da)
NO (1) NO306995B1 (da)
NZ (2) NZ275472A (da)
PL (1) PL180679B1 (da)
PT (2) PT724583E (da)
RU (1) RU2168511C2 (da)
SG (2) SG59971A1 (da)
SI (2) SI1004582T1 (da)
SK (1) SK282491B6 (da)
TW (1) TW406082B (da)
UA (1) UA60291C2 (da)
WO (1) WO1995011244A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
EP1577311A1 (en) * 1999-12-23 2005-09-21 AstraZeneca AB Salts of a pyridazino aquinoline derivative and use for the treatment of pain
EP1244453A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Method and composition for the treatment of pain
EP1244660B1 (en) * 1999-12-23 2006-03-22 AstraZeneca AB Methods and compositions for the treatment of pain
ATE274513T1 (de) * 1999-12-23 2004-09-15 Astrazeneca Ab Verbindungen und verfahren zur behandlung von schmerz
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
HUP0300313A3 (en) * 1999-12-23 2007-05-02 Astrazeneca Ab Compound, pharmaceutical composition containing it and its use for the treatment of pain
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
BR0016646A (pt) * 1999-12-23 2002-10-08 Astrazeneca Ab Método para tratar um paciente que sofre de dor, e, composição farmacêutica
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
DE60119949T2 (de) 2000-09-29 2007-04-26 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE ANWENDUNG IN DER BEHANDLUNG VON SCHMERZEN
AU2001292500A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
JP2004509964A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ 7−クロロ−4−ヒドロキシ−2−(2−ピリジルエチル)−1,2,5,10−テトラヒドロピリダジノ[4,5−b]キノリン−1,10−ジオン及び疼痛治療のためのその使用
EP1325005A1 (en) * 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain
EP1390349B1 (en) 2001-05-31 2012-07-25 Sanofi Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
EP1655301B1 (en) 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
HUT74161A (en) 1996-11-28
DE69434380T2 (de) 2006-05-04
SI1004582T1 (da) 2005-08-31
JPH09504519A (ja) 1997-05-06
IL111266A (en) 2002-03-10
FI961696A0 (fi) 1996-04-18
IL111266A0 (en) 1994-12-29
CA2171332A1 (en) 1995-04-27
UA60291C2 (uk) 2003-10-15
CN1053189C (zh) 2000-06-07
WO1995011244A1 (en) 1995-04-27
AU7944094A (en) 1995-05-08
FI970907A0 (fi) 1997-03-03
DE69434380D1 (de) 2005-06-23
AU6899998A (en) 1998-07-30
KR100261209B1 (ko) 2000-09-01
ES2154686T3 (es) 2001-04-16
FI113865B (fi) 2004-06-30
CZ113896A3 (en) 1996-09-11
DE69426422D1 (de) 2001-01-18
MY132875A (en) 2007-10-31
HK1013997A1 (en) 1999-09-17
MY124316A (en) 2006-06-30
EP1004582A3 (en) 2000-08-30
NZ329303A (en) 2000-01-28
JP3583132B2 (ja) 2004-10-27
SG59971A1 (en) 1999-02-22
PT724583E (pt) 2001-03-30
CZ292311B6 (cs) 2003-09-17
EP0724583A1 (en) 1996-08-07
SK50496A3 (en) 1997-03-05
FI114916B (fi) 2005-01-31
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
US6103721A (en) 2000-08-15
DE69426422T2 (de) 2001-05-10
RU2168511C2 (ru) 2001-06-10
DK0724583T3 (da) 2001-03-05
ES2241513T3 (es) 2005-11-01
HU9600889D0 (en) 1996-06-28
CN1138332A (zh) 1996-12-18
PL180679B1 (en) 2001-03-30
GB9420590D0 (en) 1994-11-30
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
NZ275472A (en) 1998-03-25
NO306995B1 (no) 2000-01-24
PL314041A1 (en) 1996-08-05
US6232313B1 (en) 2001-05-15
ATE295846T1 (de) 2005-06-15
ATE198072T1 (de) 2000-12-15
AU688393B2 (en) 1998-03-12
FI970907L (fi) 1997-03-03
EP1004582B1 (en) 2005-05-18
NO961584D0 (no) 1996-04-19
GR3035080T3 (en) 2001-03-30
EP0724583B1 (en) 2000-12-13
AU721139B2 (en) 2000-06-22
SG92630A1 (en) 2002-11-19
US5744471A (en) 1998-04-28
SK282491B6 (sk) 2002-02-05
EP1004582A2 (en) 2000-05-31
FI961696L (fi) 1996-04-18

Similar Documents

Publication Publication Date Title
PT1004582E (pt) Compostos de piridazino-quinolina
PT846686E (pt) Derivados de 1-fenil-pirazole e suas utilizacoes como agentes parasiticidas
DE69720965D1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
DE60038687D1 (de) 2-imino-1,3-thiazin-derivate
ATE101181T1 (de) Anti-krebs-verbindungen.
ZA924760B (en) Bicyclic fibrinogen antagonists
ATE182891T1 (de) Indazolderivate
SE9904177D0 (sv) Novel compounds
ATE132136T1 (de) Antitumor anthracenderivate
DE69316392D1 (de) Azanoradamantane
DE69011714D1 (de) Kalziumantagonisten.
GR3021344T3 (en) Benzimidazole anthelmintic agents.